Bristol-Myers Squibb’s (BMS) largest shareholder has come out against the company’s planned merger with Celgene, putting the future of the deal in doubt. The $74 billion deal, announced in ...

Revlimid, the big-selling multiple myeloma drug acquired in Bristol’s buyout of Celgene, will face a new ... in the first 9 months of 2024, but BMS expects an "additional step down” to $2 ...

The contingent value right (CVR) offered by BMS as a sweetener for the $74 billion takeover of Celgene in 2019 is defunct, as one of the three drugs – CAR-T therapy liso-cel for lymphoma ...

The GeparOcto trial was funded by Amgen, Roche, Teva, and Vifor. The GeparNuevo trial received funding from AstraZeneca and Celgene. The GAIN2 trial was supported by Amgen and BMS (Celgene).

Prior to Lilly, Winselow held senior leadership roles at BMS, Celgene, and Novartis. Winselow holds a bachelor’s degree in business administration from Howard University and a Master of Business ...

The Reko Diq copper and gold project in Pakistan could generate $74B in free cash flow over the next 37 years, based on consensus long-term prices, Barrick Gold (NYSE:GOLD) Mark Bristow said ...

Prior to Lilly, he has held senior leadership roles at BMS, Celgene, and Novartis. In a related move, Vineet Gupta, Associate VP, Managing Director, India, will transition to a new leadership role in ...

Prior to Lilly, Winselow held senior leadership roles at BMS, Celgene, and Novartis. Winselow holds a bachelor’s degree in business administration from Howard University and a Master of Business ...

Breakthrough research and investor enthusiasm prompted Cullinan Therapeutics to redirect one of its cancer programs toward ...

After two years of relatively muted investment activity, it seems that VCs are starting to pour capital into startups at pandemic-era levels once again. But a closer look shows that they aren’t ...

Prognostic Models From Transcriptomic Signatures of the Tumor Microenvironment and Cell Cycle in Stage III Colon Cancer From PETACC-8 and IDEA-France Trials Individual patient data of neoadjuvant RCTs ...